INVO Fertility, Inc. (IVF) Form 8-K — Jun 2, 2026
INVO Fertility, Inc. announced that it will restate its unaudited consolidated financial statements for the first three quarters of 2025 due to multiple accounting errors identified during an internal review. The errors involved the incorrect classification of preferred stock as mezzanine equity, improper bifurcation of embedded derivatives in convertible debentures, and incorrect accounting for debt extinguishments and warrant inducements. The audit committee concluded that the previously filed 10-Q reports for March, June, and September 2025 should no longer be relied upon, with the restatement to be presented in the forthcoming 2025 10-K.
Price after filing
Close on the filing date to close N calendar days later (from $1.52). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.